Inactive Instrument

Starpharma Holdings Limited Share Price Other OTC

Equities

SPHRY

US8555631022

Pharmaceuticals

Financials

Sales 2022 5.16M 3.43M 286M Sales 2023 4.21M 2.8M 233M Capitalization 127M 84.62M 7.06B
Net income 2022 -16M -10.64M -887M Net income 2023 -15M -9.98M -832M EV / Sales 2022 50.5 x
Net cash position 2022 41.73M 27.75M 2.31B Net cash position 2023 26.91M 17.89M 1.49B EV / Sales 2023 23.8 x
P/E ratio 2022
-18.5 x
P/E ratio 2023
-7.75 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 92.55%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 08/01
Director of Finance/CFO - 03/23/03
Corporate Officer/Principal - 12/13/12
Members of the board TitleAgeSince
Director/Board Member - 01/22/01
Chairman 79 04/13/04
Director/Board Member 53 01/20/01
More insiders
Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.
More about the company